- Home
- LTC vs NVCR Comparison
LTC vs NVCR Comparison
Compare LTC & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTC
- NVCR
- Stock Information
- Founded
- LTC 1992
- NVCR 2000
- Country
- LTC United States
- NVCR Switzerland
- Employees
- LTC N/A
- NVCR 1488
- Industry
- LTC Real Estate Investment Trusts
- NVCR Medical/Dental Instruments
- Sector
- LTC Real Estate
- NVCR Health Care
- Exchange
- LTC Nasdaq
- NVCR Nasdaq
- Market Cap
- LTC 1.7B
- NVCR 1.4B
- IPO Year
- LTC 1992
- NVCR 2015
- Fundamental
- Price
- LTC $35.61
- NVCR $12.75
- Analyst Decision
- LTC Hold
- NVCR Buy
- Analyst Count
- LTC 5
- NVCR 7
- Target Price
- LTC $38.80
- NVCR $28.79
- AVG Volume (30 Days)
- LTC 299.8K
- NVCR 1.3M
- Earning Date
- LTC 10-27-2025
- NVCR 10-29-2025
- Dividend Yield
- LTC 6.30%
- NVCR N/A
- EPS Growth
- LTC N/A
- NVCR N/A
- EPS
- LTC 1.81
- NVCR N/A
- Revenue
- LTC $213,197,000.00
- NVCR $630,160,000.00
- Revenue This Year
- LTC N/A
- NVCR $6.68
- Revenue Next Year
- LTC $30.08
- NVCR $7.01
- P/E Ratio
- LTC $20.03
- NVCR N/A
- Revenue Growth
- LTC 8.74
- NVCR 14.58
- 52 Week Low
- LTC $31.70
- NVCR $10.87
- 52 Week High
- LTC $39.89
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- LTC 41.38
- NVCR 52.27
- Support Level
- LTC $36.29
- NVCR $12.08
- Resistance Level
- LTC $36.68
- NVCR $12.83
- Average True Range (ATR)
- LTC 0.43
- NVCR 0.57
- MACD
- LTC -0.11
- NVCR 0.15
- Stochastic Oscillator
- LTC 3.17
- NVCR 49.40
About LTC LTC Properties Inc.
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in seniors housing and healthcare facilities through mortgage loans, property lease transactions, and other investments. Its real estate investments includes different types of properties such as Independent living communities, Assisted living communities, Memory care communities, Skilled nursing centers and other types of properties.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.